// App-Quantinova.ai

CT290 : PERSPECTIVE, a randomized phase 3 study

Researchers

Presenter

  • Nathan Fowler

Principal Investigators

  • Ian W. Flinn

  • Simon Rule

  • Robert Chen

  • Long Kwei

  • Alvina D. Chu

  • Leo Gordon

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Sarah Cannon Research Institute, Nashville, TN

  • University of Plymouth Peninsula Medical School, Plymouth, United Kingdom

  • City of Hope National Medical Center, Duarte, CA

  • Pharmcyclics LLC, an AbbVie Company, Sunnyvale, CA

  • Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

Biomarkers

  • Creatinine

Drug/Treatment

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02947347

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved